` Comparison: 4974 vs CYTH - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

4974
vs
CYTH

Over the past 12 months, Takara Bio Inc has significantly outperformed CYTH, delivering a return of +37% compared to the CYTH's 0% growth.

Valuation Growth Profitability Solvency Stocks Performance
Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
4974
CYTH
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
4974 CYTH
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

Intrinsic Value
603.62 JPY
Overvaluation 47%
Intrinsic Value
Price
CYTH Intrinsic Value
326.76 USD
Undervaluation 70%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Takara Bio Inc
TSE:4974
1 147 JPY
Cyclo Therapeutics Inc
NASDAQ:CYTH
99 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
4974, CYTH

4974
CYTH
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Takara Bio Inc
Revenue
Cyclo Therapeutics Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
4974, CYTH

4974
CYTH
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Takara Bio Inc
TSE:4974
Cyclo Therapeutics Inc
NASDAQ:CYTH
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Takara Bio Inc
54%
CYTH
91.2%

Operating Margin

Takara Bio Inc
-2.5%
CYTH
-2 834.1%

Net Margin

Takara Bio Inc
-16.3%
CYTH
-2 848.2%

FCF Margin

Takara Bio Inc
-19.8%
CYTH
-2 586.1%

ROE

Takara Bio Inc
-6.9%
CYTH
341.5%

ROA

Takara Bio Inc
-5.8%
CYTH
-457.1%

ROIC

Takara Bio Inc
-1.5%
CYTH
1 154.9%

ROCE

Takara Bio Inc
-1%
CYTH
340.6%

Solvency Comparison

Takara Bio Inc
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
Cyclo Therapeutics Inc
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
4974, CYTH

Loading
4974
CYTH
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
4974, CYTH

Loading
4974
CYTH
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
4974, CYTH

Loading
4974
CYTH
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 4974 to other stocks
PNEXF
Pharnext SCA
More expensive
vs Takara Bio Inc
ABBV
Abbvie Inc
Cheaper
vs Takara Bio Inc
ATXS
Astria Therapeutics Inc
More expensive
vs Takara Bio Inc
AMGN
Amgen Inc
Cheaper
vs Takara Bio Inc
Unlock Full Access to Alpha Spread
Create Free Account
ALPHA SPREAD
Follow us
Join more than 321,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett